USMLE Prep - Medical Reference Library

Minimal Change Disease (Adult) — Diagnosis & Steroid Therapy

System: Nephrology • Reviewed: Aug 31, 2025 • Step 1Step 2Step 3

Synopsis:

Adult MCD presents with nephrotic syndrome; high corticosteroid responsiveness; evaluate for secondary causes; manage complications of nephrosis.

Key Points

  • Stabilize ABCs; begin targeted evaluation without delaying life-saving therapy.
  • Use system-specific risk tools to guide testing and disposition.
  • Order high-yield tests first; escalate imaging when indicated.
  • Start evidence-based initial therapy and reassess frequently.

Algorithm

  1. Primary survey and vitals; IV access and monitors.
  2. Focused history/physical; identify red flags and likely etiologies.
  3. Order system-appropriate labs and imaging (see Investigations).
  4. Initiate guideline-based empiric therapy (see Pharmacology).
  5. Reassess response; arrange consultation and definitive management.

Clinical Synopsis & Reasoning

For Minimal Change Disease Adult Diagnosis Steroid Therapy, frame the differential by acuity and pathophysiology, then align diagnostics to the leading hypotheses. Prioritize stabilization while obtaining high‑yield studies such as BMP (Renal/electrolytes), UA ± culture (Hematuria/proteinuria/infection), Renal ultrasound (selected) (Obstruction). Incorporate bedside imaging and targeted labs to define severity and identify complications; synthesize results with clinical trajectory to refine the working diagnosis and disposition needs.


Treatment Strategy & Disposition

Initiate disease‑directed therapy alongside supportive care, titrating to objective response. Pharmacologic options commonly include IV Fluids, Electrolyte repletion. Use validated frameworks (e.g., Complication Management) to guide escalation and site of care. Address precipitating factors, de‑escalate empiric therapies with data, and arrange follow‑up for monitoring and risk‑factor modification; admit patients with instability, high risk of deterioration, or needs for close monitoring.


Management Notes

Counsel on relapse recognition and contact pathways. Coordinate VTE risk mitigation.


Epidemiology / Risk Factors

  • CKD/AKI, nephrotoxins; obstruction

Investigations

TestRole / RationaleTypical FindingsNotes
BMPRenal/electrolytesAKI/lyte changes
UA ± cultureHematuria/proteinuria/infectionFindings vary
Renal ultrasound (selected)ObstructionHydronephrosis

Complication Management

IssueAction
EdemaLoop diuretics, salt restriction
Thrombosis riskAssess and consider prophylaxis in severe hypoalbuminemia
Infection riskVaccinations; avoid live vaccines on high steroids
RelapsePrompt re‑treatment plan
Secondary causesReview meds (NSAIDs), malignancy screen

Pharmacology

MedicationMechanismOnsetRole in TherapyLimitations
AcetaminophenAnalgesic/antipyreticHoursSymptom control as appropriateHepatotoxicity (overdose)
Ondansetron5-HT3 antagonismMinutesAntiemesis if neededQT prolongation

Prognosis / Complications

  • Reversibility by cause; electrolyte/volume complications

Patient Education / Counseling

  • Explain red flags and when to seek emergent care.
  • Reinforce medication adherence and follow-up plan.

References

  1. KDIGO MCD Guidance — Link